Evotec and Bayer Advance Third Endometriosis Programme into Phase I Clinical Development

Evotec and Bayer have announced another small molecule into Phase I of their endometriosis treatment programme.

Under the strategic alliance Evotec and Bayer entered into in 2012, the goal of the collaboration is for both parties to contribute innovative drug targets, high quality technology infrastructures, and to share research and pre-clinical potential candidates in the area of endometriosis, a reproductive condition that affects approximately 176 million women worldwide. Since the start of the collaboration, three out of six non hormonal pre-clinical candidates have advanced into clinical trials.

“Since we began collaborating with Bayer in 2012, the joint teams have combined cutting-edge science, significant drug discovery expertise, and a shared commitment to bring new therapeutic options to the millions of women suffering from endometriosis” said Dr Mario Polywka, Chief Operating Officer of Evotec. “Today, we have delivered on our very high expectations with the advancement of our third novel drug candidate into Phase I studies to treat this high unmet medical need. Bayer is a great partner and we look forward to further advancing our endometriosis pipeline.”